Salix Pharmaceuticals Reports 3Q2012 Results

[at noodls] – Management Maintains 2012 Revenue Guidance of $735 Million And Increases Guidance for Adjusted Net Income to $200 Million or $3.13, Per Share, Fully Diluted 27% Increase in Year-over-Year 3Q Product Revenue … more

View todays social media effects on SLXP

View the latest stocks trending across Twitter. Click to view dashboard